SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Khosravani Nina)
 

Search: WFRF:(Khosravani Nina) > (2008) > Local treatment of ...

Local treatment of dry mouth by the cholinesterase inhibitor physostigmine

Khosravani, Nina (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology
Birkhed, Dowen, 1946 (author)
Gothenburg University,Göteborgs universitet,Institutionen för odontologi,Institute of Odontology
Ekström, Jörgen, 1944 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology
 (creator_code:org_t)
2008
2008
English.
In: 8th European Symposium on Saliva, Eeegmond oon Zee, Netherlands,14-17 june 2008.
  • Conference paper (peer-reviewed)
Abstract Subject headings
Close  
  • The feeling of mouth moistness is associated with the continuous secretion of mucin from submucosal minor glands, rather than with deficits in the watery saliva intermittently secreted from the major glands (Sreebny & Broich, 1988). Animal studies show physostigmine, applied on the oral mucosa, to enhance the cholinergic tone in the submucosal mucin-producing glands underlying the physostigmine-exposed mucosa (Ekström & Helander, 2002). Topical application of physostigmine, aiming at stimulating minor glands while at the same time minimising systemic cholinergic effects, would therefore be an advantageous approach to the treatment of mouth dryness. Presently, twenty subjects suffering from dry mouth participated, in a crossover double blind, randomized study. Physostigmine was applied onto the inside of the lips, at different doses (0.9 mg, 1.8 mg, 3.6 mg and 7.2 mg), while the vehicle served as placebo; the solution (300 ul) was distributed with the tongue. As significantly marked relief of the dry-mouth-feeling (score reduction by 25). Placebo, caused just a transient, initial, decrease in scores (by 7). Since doses above 1.8 mg were assiciated with signs of systemic effects, predominantly gastrointestinal discomfort, the dose 1.8 mg was used for objective assessment of secretion in those subjects previously tested. The volumes of saliva collected after physostigmine were significantly larger than those after placebo; the mean AUC-value (above baseline) over 180 min was almost 5 times that of placebo. Thus, physostigmine locally applied seems promising in the treatment of dry mouth.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Odontologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dentistry (hsv//eng)

Publication and Content Type

ref (subject category)
kon (subject category)

To the university's database

Find more in SwePub

By the author/editor
Khosravani, Nina
Birkhed, Dowen, ...
Ekström, Jörgen, ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Pharmacology and ...
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Dentistry
Articles in the publication
By the university
University of Gothenburg

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view